Physician profile
Matthew J Bruno
NPI 1194861849
$537,929.08
in general payments reported to CMS, 2019-2025
41 companies · $216K in 2025
The $216K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.00 · 2021: $13K · 2022: $30K · 2023: $96K · 2024: $184K · 2025: $216K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $242K · Consulting Fee: $94K · Travel and Lodging: $57K · Honoraria: $52K · Food and Beverage: $48K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $242,324.90 |
| Consulting Fee | $94,272.06 |
| Travel and Lodging | $56,907.86 |
| Honoraria | $52,312.50 |
| Food and Beverage | $47,578.02 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $806.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $132,513.88 | 2022-2024 | Vtama, Tapinarof |
| Organon LLC | $64,942.31 | 2024-2025 | Vtama |
| Abbvie INC. | $61,576.61 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $60,375.76 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $42,573.43 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $42,395.23 | 2021-2025 | |
| Amgen INC. | $30,554.72 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $14,694.59 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13,398.06 | 2021-2025 | Cabtreo, Siliq, Jublia |
| Mayne Pharma Commercial LLC | $10,765.94 | 2021-2025 | |
| Galderma Laboratories, L.P. | $9,993.77 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $8,068.10 | 2021-2025 | Sotyktu |
| Janssen Biotech, INC. | $7,504.62 | 2021-2025 | Tremfya, Remicade, Simponi |
| Incyte Corporation | $6,211.06 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $5,579.54 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $5,499.86 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $3,709.79 | 2023-2025 | Zoryve |
| Almirall LLC | $3,135.23 | 2021-2025 | Klisyri, Seysara |
| Verrica Pharmaceuticals INC. | $2,348.31 | 2023-2024 | Ycanth |
| Eli Lilly and Company | $2,049.00 | 2025 | Taltz |
| Takeda Pharmaceuticals U.S.A., INC. | $2,000.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,505.09 | 2021-2025 | Cosentyx |
| Epi Health, LLC | $1,479.59 | 2022 | |
| Vyne Pharmaceuticals INC. | $1,210.93 | 2021 | |
| Pfizer INC. | $899.49 | 2021-2025 | |
| Journey Medical Corporation | $696.72 | 2021-2025 | |
| Medimetriks Pharmaceuticals, INC. | $548.18 | 2022-2023 | Neo-Synalar |
| Botanix Sb INC | $252.49 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.49 | 2023-2024 | Spevigo, Cyltezo |
| Allergan, INC. | $214.16 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $190.41 | 2023-2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $178.77 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $137.52 | 2021 | |
| Biofrontera INC. | $116.17 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Blueprint Medicines Corporation | $114.85 | 2025 | |
| Nabriva Therapeutics, Plc | $114.55 | 2021-2022 | |
| Dermira, INC. | $49.11 | 2021 | |
| Glenmark Therapeutics INC. | $43.00 | 2019 | |
| Celgene Corporation | $27.43 | 2024 | Sotyktu |
| Helsinn Therapeutics (U.S.), INC. | $21.57 | 2025 | Valchlor |
| Sebela Pharmaceuticals INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.